Jacobi Capital Management LLC Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Jacobi Capital Management LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 0.7% during the fourth quarter, HoldingsChannel reports. The firm owned 124,916 shares of the biopharmaceutical company’s stock after buying an additional 914 shares during the period. Jacobi Capital Management LLC’s holdings in Pfizer were worth $3,314,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in PFE. Richard W. Paul & Associates LLC boosted its holdings in Pfizer by 1.9% in the fourth quarter. Richard W. Paul & Associates LLC now owns 32,299 shares of the biopharmaceutical company’s stock worth $857,000 after purchasing an additional 607 shares during the period. Metis Global Partners LLC boosted its holdings in Pfizer by 2.1% in the fourth quarter. Metis Global Partners LLC now owns 324,620 shares of the biopharmaceutical company’s stock worth $8,612,000 after purchasing an additional 6,655 shares during the period. Noble Wealth Management PBC acquired a new position in Pfizer in the fourth quarter worth $31,000. Fisher Asset Management LLC boosted its holdings in Pfizer by 79.5% in the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company’s stock worth $295,760,000 after purchasing an additional 4,938,209 shares during the period. Finally, Noesis Capital Mangement Corp boosted its holdings in Pfizer by 2.6% in the fourth quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 413 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research reports. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Wolfe Research assumed coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Finally, Guggenheim restated a “buy” rating and set a $33.00 price target on shares of Pfizer in a research report on Monday, February 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Performance

Shares of PFE opened at $26.43 on Friday. The firm has a 50-day moving average price of $26.35 and a 200 day moving average price of $27.34. The firm has a market capitalization of $149.78 billion, a PE ratio of 18.74, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the company earned $0.10 EPS. Pfizer’s revenue was up 24.7% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.51%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is presently 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.